xista science ventures

🎉 Congratulations to Cutanos GmbH on winning the prestigious 𝗕𝗔𝗥𝗗𝗔 𝗩𝗜𝗧𝗔𝗟 𝗣𝗿𝗶𝘇𝗲 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲! This award is a testament to the impact you’re making in 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀. Here's to more milestones and continued success! Cutanos is dedicated to developing next-generation vaccines incorporating its proprietary Langerhans Cell Targeting (LC-TDS) Technology. Looking ahead, the company will increase its efforts towards infectious diseases, capitalizing on the advantages of its technology to boost the efficacy and stability of mRNA vaccines, as well as high patient compliance due to pain-free skin administration. More information on Cutanos: www.cutanos.com More information on Barda Vital Prize: https://lnkd.in/dmJWY-nq #ProudInvestor #Innovation #Success #Congratulations #VentureCapital

Securing €63 million in its Series B funding round, Prewave reaches the next milestone in it's remarkable growth journey. Led by Hedosophia, this funding highlights the promising future of the company, that aims to leverage AI to help businesses manage unprecedented supply chain challenges and deliver the world’s first supply chain superintelligence platform. We at xista science ventures are proud to support the Prewave as an early-stage investor, alongside new and existing investors.   Key Takeaways: 🌍 New regulations are significantly increasing supply chain reporting and compliance requirements for businesses, amid growing global uncertainty. 🔍 Prewave's AI driven supply chain risk intelligence platform is used by customers including Toyota, Ferrari and Dr Oetker. 💡This new funding will fuel global expansion and support further product R&D. Read the full press release: https://lnkd.in/dYF-3juH About Prewave: Prewave is the future-ready sustainability, risk and compliance platform. Its best-in-class AI technology delivers an intelligent solution to businesses’ pressing supply chain challenges. Over 200 global companies including Toyota, Ferrari and Dr Oetker use Prewave to make their supply chains compliant and increase their overall resilience and sustainability. Founded in 2017, Prewave’s investors include Hedosophia, Creandum, Ventech, KOMPAS VC, Speedinvest, Working Capital Fund, seed + speed Ventures, SEGNALITA Ventures GmbH, xista science ventures and aws Gründerfonds Equity Invest GmbH & Co KG. ➡️ Find out more: www.prewave.com #VentureCapital #Startups #SustainableBusiness #SupplyChainManagement

Two xista portfolio companies are exhibiting at Innovation Corner at Technisches Museum Wien mit Österreichischer Mediathek. We are proud to announce that VALANX Biotech and Syntropic were selected to present their technologies at Innovation Corner, an exhibition highlighting exciting innovation in Lower Austria. This week, we kicked off the exhibition together with Governor Mikl-Leitner and organizers tecnet equity and accent Inkubator GmbH. Check out the Innovation Corner until September 29th. About Syntropic Medical Syntropic Medical showcase their prototype for the treatment of psychiatric disorders. Using high-frequency light pulses emitted by their goggle-like medtech device, Syntropic Medical addresses the need for non-pharmacological treatments for psychiatric disorders such as depression. ➡️Find out more: https://lnkd.in/egnvEKwW About VALANX Biotech VALANX turned their protein conjugation platform into a video game.  The site-specific protein conjugation platform of VALANX Biotech is used to exert precise control over the conjugation site and number of conjugations of their protein conjugates. Using a synthetic amino acid, they develop protein conjugates optimized for stability, low aggregation, efficacy, therapeutic window, and low immunogenicity. ➡️Find out more: https://www.valanx.bio/ #xista #Innovation #Biotech #ViennaInnovation #HealthcareInnovation #FutureOfMedicine

We are honored to have hosted the President of the European Commission, Ursula von der Leyen, at xista.   Together with xista MD Markus Wanko, the Commission President, the Minister of Finance Magnus Brunner, and ISTA President Martin Hetzer, discussed success factors and challenges in spin-off generation and growth, ranging from university incentives to capital market challenges.   A thriving innovation ecosystem, such as xista, fosters innovation, eases the path from scientific research to industrial application, and supports the growth of European spin-off companies. Institute of Science and Technology Austria and xista are primary examples of effective support from the European level: From ERC funding for research, EFRE funding for the translational lab facilities, EIC for our portfolio companies, and the EIF investment in xista science ventures.   We are honored by this recognition and look forward to many years of building and expanding this vibrant ecosystem. © Anna Stöcher | ISTA #xista #TechTransfer #ISTA #EIF #InvestEU

Congratulations to Cellectric Biosciences on winning the ultimate award – the #ViennaUp! After previously winning at Deep Tech Momentum Berlin, Cellectric founders Terje Wimberger, Klemens Wassermann move on to winning ViennaUp startup festival 2024. We are proud to support such a wonderful team. Next stop: Grand Finale San Francisco in October! ➡️ About Cellectric Cellectric provides a platform for automated electromagnetic cell modulation. Their technology provides a novel, complexity-reducing approach in the fight against sepsis-caused mortality. Find out more about Cellectric on their website: https://lnkd.in/e69KqAfp #cellectric #ViennaUP24 #StartupWorldCupAustria #entrepreneurship #electrome

Sarcura introduce their pioneering scalable on-chip detection of human white blood cells. Using silicon photonics for miniaturizing bioprocessing and analytical methods, Sarcuras on-chip flow cytometer designed in collaboration with world-leading research and innovation hub imec has been featured in Scientific Reports (Nature Publishing Group). With this, Sarcuara is one step closer to their ultimate goal of autonomous and miniaturized cell therapy production.    📢 Press release: https://lnkd.in/dXwpU2Zz  📑Full paper: https://lnkd.in/dSWwXxsw    ➡️ About Sarcura Sarcura GmbH is an Austrian based early-stage technology company, powering new possibilities in cell therapy manufacturing. While cell therapy has revolutionized cancer treatment, manufacturing patient-derived cell therapies remains a significant challenge for the industry. Issues with quality and scalability result in high therapeutic costs and limited access to life-saving treatments.   By utilizing silicon chip technology, Sarcura aims to develop a miniaturized and autonomous cell therapy manufacturing platform. This innovation is expected to increase manufacturing capacity by 100 times and reduce costs by a factor of 10, making advanced cell therapies more accessible and affordable. Learn more about Sarcura, please visit: www.sarcura.com   #Biotechnology #Innovation #IntegratedPhotonics #HighThroughput 

Congratulations Cellectric Biosciences for an outstanding performance at DeepTechMomentum! xista portfolio company Cellectric Biosciences shone bright at Deep Tech Momentum in Berlin, winning the pitch competition and three Accelerator prizes awarded by a panel of distinguished Venture Capitalists including Manuel Grossmann. Well done! ➡️ About Cellectric Cellectric provides a platform for automated electromagnetic cell modulation. Their technology provides a novel, complexity-reducing approach in the fight against sepsis-caused mortality. Find out more about Cellectric on their website: https://lnkd.in/e69KqAfp #electrome #bioelectricity #entrepreneurship #Startups

We welcome Elaia to the HEPHAISTOS-Pharma Seed Round. Securing more than €10 million from investors and prestigious non-dilutive grants, HEPHAISTOS-Pharma aims to further develop its lead product ONCO-Boost towards filing of a CTA in Europe. We at xista are proud to partner with Elaia in supporting this ambitious company. “Our consortium of seed investors brings not only the necessary funds, but also complementary expertise and a network that will structure the company. They will play a crucial role in the success of HEPHAISTOS.” said Frederic CAROFF, CEO and co-founder of HEPHAISTOS-Pharma. ▶ About HEPHAISTOS-Pharma HEPHAISTOS-Pharma develops next generation immunotherapies against cancer. Their lead drug candidate ONCO-Boost targets TLR4, kickstarting the patient's innate immune response to recognise nonresponsive tumors as immune targets. #startup #investment #drugdiscovery #immunotherapy #france #xista

Syntropic has been recognized as a 2024 Health graduate of the esteemed Creative Destruction Lab (CDL), positioning itself as a frontrunner in health innovation. Syntropic Medical is the latest addition to the xista science ventures portfolio. The pre-clinical stage medical device company is dedicated to developing new technologies that enhance the brain’s neuroplasticity, allowing for the treatment of psychiatric disorders and the improvement of cognition. Find out more on their website: www.syntropicmedical.com  #startup #scaleup #entrepreneurship #investment #BuildSomethingMassive

We're thrilled to welcome a new member to our team: Stephan Huber. Stephan joins xista science ventures as a Venture Partner. Leveraging his experience as a physician-scientist, he will focus on life science investments; making innovative approaches accessible for patients. 💬 “I am incredibly excited about the prospect of contributing to the growth and success of emerging companies in this dynamic and rapidly evolving field and to join this aspiring team on their journey.” Stephan earned his degree in medicine from the University of Munich, where he published several papers on stem cell biology in renowned journals. He capped off his academic journey with a doctoral thesis in vascular biology. Following training at several university hospitals, Stephan obtained board certification as a physician in 2015. His passion for innovation is evident in his roles as a medical head in the digital health space and as an angel investor in early-stage life science companies. At xista, we're elated to have Stephan on board, adding his brilliance to our efforts in building an ecosystem that supports scientific founders not only in Austria but also beyond. Welcome aboard, Stephan! 🚀 #VenturePartner #LifeScience #XistaScienceVentures #Innovation #NewHire #AustriaTech #StartupEcosystem